Page 4 - Layout 1

Neonatal Outcomes* Bronchopulmonary dysplasia • Neonatal death • Death within intial • hospitalization Grade III/IV Intraventricular • hemorrhage Necrotizing enterocolitis • Periventricular leukomalacia • Retinopathy of prematurity • Seizures • Sepsis • Stillbirth • *Contributors to morbidity and mortality of infants born preterm
Figure A. Analytical framework of terbutaline pump for maintenance tocolysis

Important Subgroups: KQ1a, KQ2a: <28 weeks’ gestation KQ1a, KQ2b: <32 weeks’ gestation KQ1c, KQ2c: <34 weeks’ gestation KQ1d, KQ2d: <37 weeks’ gestation KQ1e, KQ2e: multiple gestation KQ1f, KQ2f: racial or ethnic subgroups KQ1g, KQ2g: history of preterm birth KQ1h, KQ2h: history of preeclampsia KQ1i, KQ2i: RPTL

Surrogate Outcomes Gestational age at delivery • Incidence of delivery • (<28, <32, <34, <37 weeks) Mean prolongation of • pregnancy (days) Birthweight • Ratio of birthweight/ • gestational age at delivery Pregnancy prolongation • index Need for assisted ventilation • Need for oxygen per nasal • cannula NICU admission • (KQ6) Pump Failure

(KQ5)

(KQ2) Treatment with terbutaline pump as compared with placebo, conservative treatment, or other interventions Confounders (level of care, level of activity and cointerventions)

Pregnant women with arrest of preterm labor (24-36 (KQ3, KQ4) Maternal Side Effects Heart failure Hyperglycemia Hypokalemia Maternal mortality Myocardial infarction Pulomonary edema Hypotension Maernal discontinuation Withdrawl-AE Neonatal Side Effects Hypoglycemia Hypocalcemia

(KQ1) weeks’ gestation) Arrhythmia • • • • • • • • • of therapy • • • Ileus •

4